CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 221 enrolled
Drug / intervention
Hydroxychloroquinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04333225
NCT04333225Phase 2Completed
CompareCT.gov

A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures

Baylor Research Institute·interventional·Posted Apr 3, 2020·Updated Aug 20, 2021

In Brief

A Phase 2 clinical trial evaluating Hydroxychloroquine for COVID-19. Completed, enrolled 221 participants across 1 site.

Detailed Summary

In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt not to receive the study drug will form the control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 3, 2020
Enrollment StartApr 3, 2020
Primary CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.2 years ago

Interventions

Hydroxychloroquinedrug

Weekly treatment in individuals at high risk